Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lieber

Showing results (531-540 of 556) with videos related to

Pageof 56
Sort By:
JCI Insight|July 13, 2018
Antibody-modified conduits for highly selective cytokine elimination from bloodJ Brian McAlvin, Ryan G Wylie, Krithika Ramchander, et al.
Nature Communications|July 29, 2022
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster modelCarolin M Lieber, Robert M Cox, Julien Sourimant, et al.
Nature Communications|August 7, 2023
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal modelsRobert M Cox, Carolin M Lieber, Josef D Wolf, et al.
Science (New York, N.Y.)|December 2, 2021
4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replicationJulien Sourimant, Carolin M Lieber, Megha Aggarwal, et al.
Neuron|December 1, 2019
Single-Cell Profiles of Retinal Ganglion Cells Differing in Resilience to Injury Reveal Neuroprotective GenesNicholas M Tran, Karthik Shekhar, Irene E Whitney, et al.
Biorxiv : the Preprint Server for Biology|December 1, 2022
Paxlovid-like nirmatrelvir/ritonavir fails to block SARS-CoV-2 transmission in ferretsRobert M Cox, Carolin M Lieber, Josef D Wolf, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2021
4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replicationJulien Sourimant, Carolin M Lieber, Megha Aggarwal, et al.
The Journal of Urology|October 12, 2000
A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinomaK C Halling, W King, I A Sokolova, et al.
The New England Journal of Medicine|June 26, 2003
The influence of finasteride on the development of prostate cancerIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.
Urology|April 10, 1999
Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study GroupP B Hudson, R Boake, J Trachtenberg, et al.
Pageof 56

Showing results (531-540 of 556) with videos related to

Sort By:
Pageof 56
JCI Insight|July 13, 2018
Antibody-modified conduits for highly selective cytokine elimination from bloodJ Brian McAlvin, Ryan G Wylie, Krithika Ramchander, et al.
Nature Communications|July 29, 2022
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster modelCarolin M Lieber, Robert M Cox, Julien Sourimant, et al.
Nature Communications|August 7, 2023
Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal modelsRobert M Cox, Carolin M Lieber, Josef D Wolf, et al.
Science (New York, N.Y.)|December 2, 2021
4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replicationJulien Sourimant, Carolin M Lieber, Megha Aggarwal, et al.
Neuron|December 1, 2019
Single-Cell Profiles of Retinal Ganglion Cells Differing in Resilience to Injury Reveal Neuroprotective GenesNicholas M Tran, Karthik Shekhar, Irene E Whitney, et al.
Biorxiv : the Preprint Server for Biology|December 1, 2022
Paxlovid-like nirmatrelvir/ritonavir fails to block SARS-CoV-2 transmission in ferretsRobert M Cox, Carolin M Lieber, Josef D Wolf, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2021
4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replicationJulien Sourimant, Carolin M Lieber, Megha Aggarwal, et al.
The Journal of Urology|October 12, 2000
A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinomaK C Halling, W King, I A Sokolova, et al.
The New England Journal of Medicine|June 26, 2003
The influence of finasteride on the development of prostate cancerIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.
Urology|April 10, 1999
Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study GroupP B Hudson, R Boake, J Trachtenberg, et al.
Pageof 56